Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
X4 Pharmaceuticals Announces FDA Fast Track Designation Granted to Mavorixafor for the Treatment of WHIM Syndrome
BOSTON, Oct. 08, 2020 - X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resul…
First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
GAITHERSBURG, MD -- October 6, 2020 – NexImmune, a clinical-stage biotechnology company developing a portfolio of unique non-genetically-engineered T …
Affimed Doses First Patient in Phase 1 Clinical Trial of Natural Killer Cells in Combination with AFM13
Heidelberg, Germany, October 6, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their i…
Verastem Oncology Announces Closing of Duvelisib Sale to Secura Bio
BOSTON - Sep. 30, 2020 - Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medici…
Patient Education Webcasts
Insight into Chronic Myeloid Leukemia (CML)
NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed AML
GAITHERSBURG, MD - September 23, 2020 – NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunoth…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
